Department of Medical Oncology, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.
Department of Oncology, University of Calgary, Calgary, Alberta T2N 4N2, Canada.
World J Gastroenterol. 2019 Jan 7;25(1):59-68. doi: 10.3748/wjg.v25.i1.59.
Colorectal cancer (CRC) is a prevalent disease and represents a major cause of morbidity and mortality in the developed world. Intensive post-treatment surveillance is routinely recommended by major expert groups for early stage (II and III) CRC survivors because previous meta-analyses showed a modest, but significant survival benefit. This practice has been recently challenged based on data emerging from several large phase III randomized trials that demonstrated a lack of survival benefit from intensive surveillance strategies. In addition, findings from cost-effectiveness analyses of such an approach are inconsistent. Data on real-world practice, specifically adherence to these follow-up guidelines, are also limited. The debate is especially controversial in resected stage IV patients where there are currently no clear guidelines for follow-up. In an era of personalized medicine, there may be a shift towards a more risk-adapted approach to better define the optimal follow-up strategy. In this article, we review the evidence and highlight the role of surveillance in CRC survivors.
结直肠癌(CRC)是一种常见疾病,在发达国家是发病率和死亡率的主要原因。主要专家组常规建议对 II 期和 III 期 CRC 幸存者进行强化治疗后监测,因为之前的荟萃分析显示,这种监测方法可适度提高生存率,尽管效果并不显著。最近,基于几项大型 III 期随机试验的数据,该做法受到了挑战,这些试验表明强化监测策略并不能带来生存获益。此外,对这种方法进行成本效益分析的结果也不一致。关于实际做法的数据,特别是对这些随访指南的依从性数据也很有限。在目前尚无明确随访指南的切除后 IV 期患者中,这场争论尤其具有争议性。在个体化医学时代,可能会向更具风险适应性的方法转变,以更好地确定最佳随访策略。在本文中,我们将回顾相关证据,并强调监测在 CRC 幸存者中的作用。